BioPharmSignal logoBioPharmSignal

Biotech News

Amgen wins FDA approval for late-stage oncology treatment

Amgen (AMGN)amgen.com2026-04-03 09:15 ESTFDA / regulatory

Amgen (AMGN) appears in the live feed after an FDA catalyst that can change the stock's tone quickly.

The source domain is amgen.com. BioPharmSignal keeps the ticker, timestamp, and source together so readers can move from signal to source without leaving the flow.

The original release is available below in a new tab so you can continue into the full source when needed.

Open original release

Related news

No closely related headlines were available from the latest feed snapshot.

View all latest news

Amgen Inc.

Amgen is a large-cap biopharmaceutical company with a commercial base spanning oncology, inflammation, bone health, cardiovascular disease, and rare disease. Investors follow the stock for the mix of marketed products, late-stage pipeline optionality, and recurring regulatory or launch milestones.

Recent company news

AMGNamgen.com2026-04-03 09:15 EST

FDA approves late-stage oncology treatment

AMGNamgen.com2026-04-01 08:05 EST

Management commentary keeps pipeline priorities in focus

AMGNnewswire2026-03-28 16:20 EST

Investors watch oncology and cardiometabolic launch cadence

AMGNsec.gov2026-03-21 07:50 EST

Regulatory calendar keeps Amgen in the spotlight

AMGNconference2026-03-15 10:10 EST

Pipeline updates reinforce the commercial-stage narrative

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
Thousand Oaks, California